al differences cannot be excluded.

Aims:
The goal of this study was to investigate the expressions of ERC4, 				ERD5 and ERD3 variant messenger RNAs in normal breast tissues and their matched 				adjacent primary breast tumor tissues.

Materials and methods:
Eighteen cases were selected from the Manitoba Breast Tumor Bank, 				which had well separated and histopathologically characterized normal and 				adjacent neoplastic components. All tumors were classified as primary invasive 				ductal carcinomas. Six tumors were ER-negative/progesterone receptor 				(PR)-negative, nine were ER-positive/PR-positive, two were 				ER-positive/PR-negative, and one was ER-negative/PR-positive, as measured by 				ligand-binding assay. For each specimen, total RNA wa